Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)
Johnson & Johnson (JNJ) posted Construction in Progress of $4.3 billion for Q1 2021, up 18.67% sequentially from $3.6 billion in Q4 2019, and up 18.67% YoY from $3.6 billion in Q1 2020.
Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021) Analysis & Trends
Johnson & Johnson has reported Construction in Progress for 10 years, with the latest figure at $4.3 billion in Q1 2021.
- Quarterly Construction in Progress rose 18.67% year-over-year to $4.3 billion in Q1 2021, while the trailing twelve-month figure through Jan 2021 was $4.3 billion (up 18.67% YoY) and the FY2021 annual result came in at $4.3 billion, up 18.67% from the prior year.
- Construction in Progress improved to $4.3 billion in Q1 2021 per JNJ's latest filing, from $3.6 billion in the prior quarter.
- Over five years, Construction in Progress peaked at $4.3 billion in Q1 2021 and troughed at $3.4 billion in Q1 2017.
- A 4-year average of $3.7 billion and a median of $3.6 billion in 2019 frame the typical range for Construction in Progress.
- The sharpest annual moves came in 2019 and 2021: Construction in Progress declined 6.17% in 2019, then advanced 18.67% in 2021.
- Over 4 years, Construction in Progress stood at $3.4 billion in 2017, then climbed by 12.41% to $3.9 billion in 2018, then slipped by 6.17% to $3.6 billion in 2019, then grew by 18.67% to $4.3 billion in 2021.
- According to Business Quant data, Construction in Progress over the past three periods registered $4.3 billion, $3.6 billion, and $3.9 billion for Q1 2021, Q4 2019, and Q4 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.98 Bn | 627.22 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.45 Bn | 459.88 Bn | 12.70 Bn | - |
| 3 | Merck | 372.04 Bn | 364.90 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 299.31 Bn | 291.62 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 256.25 Bn | 251.35 Bn | 12.86 Bn | - |
| 6 | Amgen | 235.50 Bn | 221.52 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.26 Bn | 147.56 Bn | 10.94 Bn | - |
| 9 | Gsk | 104.79 Bn | 100.62 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.62 Bn | 47.24 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 3, 2021 | 4.32 Bn |
| Dec 29, 2019 | 3.64 Bn |
| Dec 30, 2018 | 3.88 Bn |
| Dec 31, 2017 | 3.45 Bn |
| Jan 1, 2017 | 3.35 Bn |
| Jan 3, 2016 | 3.53 Bn |
| Dec 28, 2014 | 3.60 Bn |
| Dec 29, 2013 | 3.30 Bn |
| Dec 30, 2012 | 2.74 Bn |
| Jan 1, 2012 | 2.50 Bn |
| Jan 2, 2011 | 2.58 Bn |
| Jan 3, 2010 | 2.52 Bn |